ALNY

$0.00

(

+0.00%

)
Quote details

stock

Alnylam Pharmaceuticals Inc

NASDAQ | ALNY

458.41

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 17, 2025)

$59.98B

Market Cap

1448.9

P/E Ratio

0.31

EPS

$495.55

52 Week High

$205.87

52 Week Low

HEALTHCARE

Sector

ALNY Chart

Recent Chart
Price Action

ALNY Technicals

Tags:

ALNY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

Revenue & Profitability

Earnings Performance

ALNY Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4.2B
Total Current Assets $3.3B
Cash And Cash Equivalents At Carrying Value $966M
Cash And Short Term Investments $966M
Inventory $79M
Current Net Receivables $405M
Total Non Current Assets $945M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $1.7B
Other Current Assets $117M
Other Non Current Assets -
Total Liabilities $4.2B
Total Current Liabilities $1.2B
Current Accounts Payable $88M
Deferred Revenue -
Current Debt -
Short Term Debt $155M
Total Non Current Liabilities $3B
Capital Lease Obligations $271M
Long Term Debt $1B
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.7B
Other Current Liabilities $887M
Other Non Current Liabilities $1.7B
Total Shareholder Equity $67M
Treasury Stock -
Retained Earnings -$7.3B
Common Stock $1.3M
Common Stock Shares Outstanding $128M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$8.3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $57M
Capital Expenditures $34M
Change In Receivables -
Change In Inventory $14M
Profit Loss -
Cashflow From Investment -$117M
Cashflow From Financing $294M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$278M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

ALNY News

ALNY Profile

Alnylam Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development and commercialization of transformative RNA interference (RNAi) therapeutics aimed at addressing genetic diseases. The company boasts a robust pipeline of innovative RNAi-based therapies and has made significant strides in the market, including the successful launch of its first commercial product. With a steadfast commitment to scientific excellence and the advancement of medicine, Alnylam is positioned as a leader in the biopharmaceutical sector, striving to redefine treatment paradigms for both rare and prevalent diseases.

LPTX
+368.57%
$2.05
WTO
+18.41%
$0.02
VINE
+1.80%
$0.40
AMIX
+69.18%
$1.23
VHAI
+33.33%
$0.00
ASST
-6.08%
$1.08
CHR
+2.05%
$0.04
SOFI
-2.00%
$27.82
ETHD
+1.75%
$5.23
KXIN
+67.93%
$0.51
GLMD
+26.92%
$1.32
AXDX
-61.36%
$0.03
APLT
+10.62%
$0.24
GNS
+3.95%
$0.89
ADAP
-15.14%
$0.05
BMNR
-5.93%
$34.40
IREN
-4.68%
$46.37
ONDS
-11.97%
$6.31
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
SRM
+53.27%
$10.30
MSPR
+13.44%
$0.50
QUBT
+10.28%
$11.69
RXRX
-4.38%
$4.14
TSLA
+2.48%
$414.40
WLGS
-5.57%
$0.04
DFLI
+3.73%
$0.84
NVDA
-0.69%
$188.84
MTSR
-0.35%
$70.50
PLUG
-5.34%
$2.12
BYND
-2.77%
$1.05
TWOH
0.00%
$0.00
AFMD
-34.94%
$0.18
WMT
-0.05%
$102.48
BURU
-8.80%
$0.22
PCG
-0.96%
$16.49
ASBP
-8.93%
$0.09
PFE
+1.27%
$25.38
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
RIVN
+0.06%
$15.12
RCAT
-7.49%
$7.16
AMC
-2.56%
$2.28
AMZN
-1.98%
$230.02
PLTR
-1.64%
$171.14
INTC
+0.14%
$35.57
ET
+2.28%
$17.01
MARA
-1.15%
$11.85
KDLY
-1.68%
$0.61
RGTI
+0.03%
$25.49
NIO
-1.04%
$6.09
SAND
-6.04%
$12.12
GOOGL
+5.81%
$292.48
XPEV
-5.76%
$23.56
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
AMD
-0.58%
$245.36
VEEE
-8.09%
$1.59
GOOG
+5.01%
$290.87
WULF
+3.13%
$11.33
DVLT
-0.95%
$1.81
GPUS
-6.97%
$0.26
UEC
0.00%
$11.59
CPRT
-1.29%
$41.08
COIN
+0.30%
$284.00
IVVD
+23.82%
$2.91
HLN
-3.13%
$9.59
CGTL
+23.74%
$0.82
LCID
-6.39%
$14.20
CIFR
+0.80%
$14.47
RIG
+3.11%
$4.13
ACHR
-3.44%
$7.60
NEHC
-5.19%
$4.01
OWL
-1.34%
$14.62
AAPL
-1.19%
$269.14
LYG
-1.22%
$4.82
NBIS
+5.21%
$87.89
GLXY
-3.30%
$26.34
CMND
-1.08%
$0.28
SNAP
-2.56%
$8.35
NEM
-2.14%
$87.80
IONQ
+3.84%
$48.99
HPE
-4.79%
$21.73
TLRY
0.00%
$1.08
SMCI
-4.12%
$34.91
BABA
+3.84%
$159.72
QBTS
-0.95%
$23.38
TOI
+28.89%
$3.97
CRCL
-4.79%
$77.96
MU
+4.16%
$257.09
F
-0.68%
$13.10
FL
-0.37%
$24.01
NVVE
-10.58%
$0.23
YMM
-9.29%
$11.17
PLTD
+1.72%
$6.95
GERN
-2.60%
$1.12
HOOD
-3.53%
$118.16
ETHE
-0.92%
$25.75
CLSK
-1.23%
$10.82
LPTX
+368.57%
$2.05
WTO
+18.41%
$0.02
VINE
+1.80%
$0.40
AMIX
+69.18%
$1.23
VHAI
+33.33%
$0.00
ASST
-6.08%
$1.08
CHR
+2.05%
$0.04
SOFI
-2.00%
$27.82
ETHD
+1.75%
$5.23
KXIN
+67.93%
$0.51
GLMD
+26.92%
$1.32
AXDX
-61.36%
$0.03
APLT
+10.62%
$0.24
GNS
+3.95%
$0.89
ADAP
-15.14%
$0.05
BMNR
-5.93%
$34.40
IREN
-4.68%
$46.37
ONDS
-11.97%
$6.31
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
SRM
+53.27%
$10.30
MSPR
+13.44%
$0.50
QUBT
+10.28%
$11.69
RXRX
-4.38%
$4.14
TSLA
+2.48%
$414.40
WLGS
-5.57%
$0.04
DFLI
+3.73%
$0.84
NVDA
-0.69%
$188.84
MTSR
-0.35%
$70.50
PLUG
-5.34%
$2.12
BYND
-2.77%
$1.05
TWOH
0.00%
$0.00
AFMD
-34.94%
$0.18
WMT
-0.05%
$102.48
BURU
-8.80%
$0.22
PCG
-0.96%
$16.49
ASBP
-8.93%
$0.09
PFE
+1.27%
$25.38
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
RIVN
+0.06%
$15.12
RCAT
-7.49%
$7.16
AMC
-2.56%
$2.28
AMZN
-1.98%
$230.02
PLTR
-1.64%
$171.14
INTC
+0.14%
$35.57
ET
+2.28%
$17.01
MARA
-1.15%
$11.85
KDLY
-1.68%
$0.61
RGTI
+0.03%
$25.49
NIO
-1.04%
$6.09
SAND
-6.04%
$12.12
GOOGL
+5.81%
$292.48
XPEV
-5.76%
$23.56
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
AMD
-0.58%
$245.36
VEEE
-8.09%
$1.59
GOOG
+5.01%
$290.87
WULF
+3.13%
$11.33
DVLT
-0.95%
$1.81
GPUS
-6.97%
$0.26
UEC
0.00%
$11.59
CPRT
-1.29%
$41.08
COIN
+0.30%
$284.00
IVVD
+23.82%
$2.91
HLN
-3.13%
$9.59
CGTL
+23.74%
$0.82
LCID
-6.39%
$14.20
CIFR
+0.80%
$14.47
RIG
+3.11%
$4.13
ACHR
-3.44%
$7.60
NEHC
-5.19%
$4.01
OWL
-1.34%
$14.62
AAPL
-1.19%
$269.14
LYG
-1.22%
$4.82
NBIS
+5.21%
$87.89
GLXY
-3.30%
$26.34
CMND
-1.08%
$0.28
SNAP
-2.56%
$8.35
NEM
-2.14%
$87.80
IONQ
+3.84%
$48.99
HPE
-4.79%
$21.73
TLRY
0.00%
$1.08
SMCI
-4.12%
$34.91
BABA
+3.84%
$159.72
QBTS
-0.95%
$23.38
TOI
+28.89%
$3.97
CRCL
-4.79%
$77.96
MU
+4.16%
$257.09
F
-0.68%
$13.10
FL
-0.37%
$24.01
NVVE
-10.58%
$0.23
YMM
-9.29%
$11.17
PLTD
+1.72%
$6.95
GERN
-2.60%
$1.12
HOOD
-3.53%
$118.16
ETHE
-0.92%
$25.75
CLSK
-1.23%
$10.82

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.